CAMBRIDGE, Mass., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has received a closeout letter from the Office of Prescription Drug Promotion (OPDP) signifying the resolution of the Warning Letter in regard to statements made about JUXTAPID® during two 2013 television broadcast interviews. In light of corrective actions taken by Aegerion, including disseminating a corrective broadcast, OPDP considers the matter closed effective August 25, 2014.
"We worked closely with OPDP to resolve the issues raised in the Warning Letter and are pleased that OPDP considers the matter closed," said Martha J. Carter, Chief Regulatory Officer and Senior Vice President. "We take very seriously our obligation to comply with all FDA requirements, including those pertaining to promotion of our product."
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.